BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Clinical trials sought for Ivaltinostat in treating acute pneumonia or fibrosis caused by COVID-19

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : September 15, 2020, 16:45 | Updated : September 15, 2020, 16:45
  • 트위터
  • 페이스북
  • 웨이보
 

[Courtesy of Crystal Genomics]


SEOUL -- Crystal Genomics, a biopharmaceutical company in South Korea, will carry out clinical trials to see if its novel drug candidate, Ivaltinostat, is effective in treating acute pneumonia or fibrosis caused by a novel coronavirus.

Crystal Genomics has developed Ivalinostat for various indications such as liver cancer and fibrosis. The company claimed to have confirmed the anti-inflammatory effect of Ivaltinostat by administering it with Camostat to hamster models infected with COVID-19.

Camostat, a serine protease inhibitor, has been approved in Japan for the treatment of chronic pancreatitis and postoperative reflux esophagitis. Clinical trials are underway in South Korea to test the safety and efficacy of candidates for COVID-18 treatment that included camostat mesilate.

Crystal Genomics will carry out second-stage clinical trials in the U.S. and other countries to test the efficacy of Ivaltinostata as a sole COVID-19 treatment. In partnership with Parexel, a U.S.-based company, CrystalGenomics is in the process of obtaining approval from the U.S. Food and Drug Administration (FDA) for the second phase of clinical trials.

 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Semiconductor-based fast test kit using saliva able to debut in March: science minister.
    Semiconductor-based fast test kit using saliva able to debut…
  • .Syringes for COVID-19 vaccines added to list of K-quarantine technologies.
    Syringes for COVID-19 vaccines added to list of 'K-quarantin…
  • .Health officials heave sigh of relief at early introduction of Novavax vaccine .
    Health officials heave sigh of relief at early introduction …
  • .Bukwangs COVID-19 treatment wins FDA approve to go ahead with second-phase clinical trials.
    Bukwang's COVID-19 treatment wins FDA approve to go ahead wi…
  • .Experts give conditional consent to AstraZenecas vaccine for people over 65.
    Experts give conditional consent to AstraZeneca's vaccine fo…

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Prime Minister Chung stresses importance of 'borderless communication channel' to minimize informati…
  • State hospital succeeds in inserting wireless pacemakers into hearts of bradyarrhythmia patients
  • LG Electronics' joint venture with Canada's Magna awaits approval by shareholders in March
  • Sajo Seafood to launch raw tuna menu delivery service
  • Researchers find new roundworm species near Dokdo
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view